Catalyst
Slingshot members are tracking this event:
Halozyme Therapeutics (HALO) to begin Phase 1b open label study—under MORPHEUS platform—on combination Tecentriq and PEG PH20 treating metastatic biliary of gallbladder cancer in second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HALO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 08, 2017
Occurred Source:
http://www.halozyme.com/investors/news-releases/news-release-details/2017/Halozyme-Reports-Second-Quarter-2017-Results/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Morpheus, Phase 1b, Tecentriq, Pegph20, Metastatic Biliary, Gallbladder Tumors
